Sepsis, septic shock, vasopressors, inotropic, vasoplegiaSepsis, Choque séptico, vasopresores, inotrópicos, vasoplejía

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet (London, England) 2020;395:200-11.
2. Allen JM, Feild C, Shoulders BR, Voils SA. Recent Updates in the pharmacological management of sepsis and septic shock: a systematic review focused on fluid resuscitation, vasopressors, and corticosteroids. Ann Pharmacother, 2019;53:385-95.
3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10.
4. Ospina-Tascón GA, Hernandez G, Bakker J. Should we start vasopressors very early in septic shock? J Thorac Dis. 2020;12:3893-6.
5. Nandhabalan P, Ioannou N, Meadows C, Wyncoll D. Refractory septic shock: our pragmatic approach. Crit Care. 2018;22:215.
6. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Crit Care Med. 2018;46:997-1000. https://doi.org/10.1097/CCM.0000000000003119
7. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44:925-8. https://doi.org/10.1007/s00134-018-5085-0
8. Bai X, Yu W, Ji W, Lin Z, Tan S, Duan K, et al. Early versus delayed administration of norepinephrine in patients with septic shock. Crit Care. 2014;18:532.
9. Cheng L, Yan J, Han S, Chen Q, Chen M, Jiang H, et al. Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials. Crit Care. 2019;23(1):168. https://doi.org/10.1186/s13054-019-2427-4
10. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:762-74.
11. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:775-87.
12. Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015;20:249-60.
13. Carrillo-Esper R, Leal-Gaxiola P. Actualidades de fármacos vasopresores e inotrópicos en anestesia. Rev Mex Anestesiol. 2009;32:S74-76.
14. Overgaard CB, Dzavík V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118:1047-56.
15. Stratton L, Berlin DA, Arbo JE. Vasopressors and Inotropes in Sepsis. Emerg Med Clin North Am. 2017;35:75-91.
16. Hamzaoui O, Scheeren TWL, Teboul J-L. Norepinephrine in septic shock: when and how much? Curr Opin Crit Care. 2017;23:342-7.
17. Hamzaoui O, Jozwiak M, Geffriaud T, Sztrymf B, Prat D, Jacobs F, et al. Norepinephrine exerts an inotropic effect during the early phase of human septic shock. Br J Anaesth. 2018;120:517-24.
18. De Backer D, Pinsky M. Norepinephrine improves cardiac function during septic shock, but why? Br J Anaesth. 2018;120:421-4.
19. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-89.
20. De Backer D, Aldecoa C, Njimi H, Vincent J-L. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med. 2012;40:725-30.
21. Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One. 2015;10:e0129305.
22. Branco RG. Dopamine in sepsis-beginning of the end? Pediatr Crit Care Med. 2016;17:1099-100.
23. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2021. Intensive Care Med. 2021;47:1181-247.
24. Beck GC, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, van der Woude FJ, et al. Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care. 2004;8:485-91.
25. Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526-31.
26. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med. 2002;28:877-83.
27. Colling KP, Banton KL, Beilman GJ. Vasopressors in Sepsis. Surg Infect (Larchmt) 19:202-7.
28. Mahmoud KM, Ammar AS. Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock. Indian J Crit Care Med. 2012;16:75-80.
29. Annane D, Vignon P, Renault A, Bollaert P-E, Charpentier C, Martin C, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet (London, England). 2007;370:676-84.
30. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34:2226-34.
31. Kam PCA, Williams S, Yoong FFY. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia. 2004;59:993-1001.
32. Meresse Z, Medam S, Mathieu C, Duclos G, Vincent J-L, Leone M. Vasopressors to treat refractory septic shock. Minerva Anestesiol. 2020;86.
33. Russell JA, Wellman H, Walley KR. Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. J intensive care. 2018;6:73.
34. Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D’Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122-5.
35. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576-82.
36. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH Randomized Clinical Trial. JAMA. 2016;316:509-18.
37. Severson KA, Ritter-Cox L, Raffa JD, Celi LA, Gordon WJ. Vasopressin administration is associated with rising serum lactate levels in patients with sepsis. J Intensive Care Med. 2020;35:881-8.
38. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877-87.
39. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med. 2009;37:811-8.
40. McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA. 2018;319:1889-900.
41. Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med. 2019;45:844-55.
42. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Laderchi A, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care. 2008;12:R143.
43. Aschenbrenner DS. New Hypotension Treatment for Septic Shock. Am J Nurs. 2018;118:22.
44. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory Shock. N Engl J Med. 2017;377:419-30.
45. Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care. 2016;4:22.
46. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 2014;5:213-8.
47. Ospina-Tascón GA, Calderón-Tapia LE. Inodilators in septic shock: should these be used? Ann Transl Med. 2020;8:796.
48. Sato R, Ariyoshi N, Hasegawa D, Crossey E, Hamahata N, Ishihara T, et al. Effects of Inotropes on the Mortality in Patients With Septic Shock. J Intensive Care Med. 2021;36:211-9.
49. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96:47G-58G.
50. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
51. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683-93.
52. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. Health Technol Assess. 2015;19:i-xxv, 1-150.
53. Peake SL, Bailey M, Bellomo R, Cameron PA, Cross A, Delaney A, et al. Australasian resuscitation of sepsis evaluation (ARISE): a multi-centre, prospective, inception cohort study. Resuscitation. 2009;80:811-8.
54. Sato R, Nasu M. Time to re-think the use of dobutamine in sepsis. J Intensive Care. 2017;5:65.
55. Osborn TM. Severe Sepsis and Septic Shock Trials (ProCESS, ARISE, ProMISe): What is Optimal Resuscitation? Crit Care Clin. 2017;33:323-44.
56. Magder S. Volume and its relationship to cardiac output and venous return. Crit Care. 2016;20:271.
57. Magder S. Erratum to: Volume and its relationship to cardiac output and venous return. Crit Care. 2017;21:16.
58. Serpa Neto A, Nassar AP, Cardoso SO, Manetta JA, Pereira VGM, Espósito DC, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012;16:R154.
59. Belletti A, Benedetto U, Biondi-Zoccai G, Leggieri C, Silvani P, Angelini GD, et al. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. J Crit Care. 2017;37:91-8.
60. Kislitsina ON, Rich JD, Wilcox JE, Pham DT, Churyla A, Vorovich EB, et al. Shock - classification and pathophysiological principles of therapeutics. Curr Cardiol Rev. 2019;15:102-13.
61. Clinicaltrials. Milrinone versus placebo in patients with septic shock [internet]. Disponible en: https://clinicaltrials.gov/ct2/show/study/NCT05122884
62. Tomicic V, Zouein L, Espinoza J, Ugarte S. Milrinone role in treatment of septic shock. Crit Care. 2015;19:P154.
63. Tomicic V, Zouein L, Iribarren G, Arenas Á. Rol de la milrinona en el tratamiento del shock séptico Milrinone role in treatment of septic shock. Rev Chil Med Intensiva. 2022;36:61-71.
64. Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N Engl J Med. 2021;385:516-25.
65. Lehtonen L, Põder P. The utility of levosimendan in the treatment of heart failure. Ann Med. 2007;39:2-17.
66. Greco T, Calabrò MG, Covello RD, Greco M, Pasin L, Morelli A, et al. A Bayesian network meta-analysis on the effect of inodilatory agents on mortality. Br J Anaesth. 2015;114:746-56.
67. Zangrillo A, Putzu A, Monaco F, Oriani A, Frau G, De Luca M, et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials. J Crit Care. 2015;30:908-13.
68. Bhattacharjee S, Soni KD, Maitra S, Baidya DK. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: a meta-analysis of randomized controlled trials. J Clin Anesth. 2017;39:67-72.
69. Chang W, Xie JF, Xu JY, Yang Y. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials. BMJ Open. 2018;8:1-8.
70. Zampieri FG, Machado FR, Biondi RS, Freitas FGR, Veiga VC, Figueiredo RC, et al. Effect of intravenous fluid treatment with a balanced solution vs 0.9% saline solution on mortality in critically ill patients: the BaSICS Randomized Clinical Trial. JAMA. 2021;326(9):1-12. https://doi.org/10.1001/jama.2021.11684
71. Zampieri FG, Machado FR, Biondi RS, Freitas FGR, Veiga VC, Figueiredo RC, et al. Effect of slower vs faster intravenous fluid bolus rates on mortality in critically ill patients: The BaSICS Randomized Clinical Trial. JAMA 2021;326(9):830-8. https://doi.org/10.1001/jama.2021.11444
72. Meyhoff TS, Hjortrup PB, Wetterslev J, Sivapalan P, Laake JH, Cronhjort M, et al. Restriction of intravenous fluid in ICU patients with septic shock. N Engl J Med. 2022;386:2459-70.
73. Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki L-M, Pettilä V. Hemodynamic variables related to outcome in septic shock. Intensive Care Med. 2005;31:1066-71.
74. Dünser MW, Takala J, Ulmer H, Mayr VD, Luckner G, Jochberger S, et al. Arterial blood pressure during early sepsis and outcome. Intensive Care Med. 2009;35:1225-33.
75. Maheshwari K, Nathanson BH, Munson SH, Khangulov V, Stevens M, Badani H, et al. The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med. 2018;44:857-67.
76. Russell JA, Gordon AC, Walley KR. Early May be better: early low-dose norepinephrine in septic shock. Am J Respir Crit Care Med. 2019;199:1049-51.
77. Nishikawa M, Mak JC, Shirasaki H, Harding SE, Barnes PJ. Long-term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary beta-adrenergic receptors in guinea pigs. Am J Respir Cell Mol Biol. 1994;10:91-9.
78. Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early use of norepinephrine in septic shock resuscitation (CENSER): a randomized trial. Am J Respir Crit Care Med. 2019;199:1097-105.
79. Hammond DA, Ficek OA, Painter JT, McCain K, Cullen J, Brotherton AL, et al. Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy. 2018;38:531-8.
80. Morimatsu H, Singh K, Uchino S, Bellomo R, Hart G. Early and exclusive use of norepinephrine in septic shock. Resuscitation. 2004;62:249-54.
81. Hamzaoui O, Georger J-F, Monnet X, Ksouri H, Maizel J, Richard C, et al. Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. Crit Care. 2010;14:R142.
82. Yeo HJ, Lee YS, Kim TH, Jang JH, Lee HB, Oh DK, et al. Vasopressor initiation within 1 hour of fluid loading is associated with increased mortality in septic shock patients: analysis of national registry data. Crit Care Med. 2022;50:e351-60.
83. Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen J-T, Phillips KM, et al. Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med. 2020;48:1445-53.

Vol. 64 No. 2 (2023)